10-Q: MIRA Pharmaceuticals Faces Going Concern, Nasdaq Risk

MIRA Pharmaceuticals reports significant cash burn and Nasdaq non-compliance, raising substantial doubt about its ability to continue as a going concern, despite advancing its neuroscience drug pipeline.

Summary

• MIRA Pharmaceuticals, a clinical-stage company, reported a net loss of $3.32 million for the six months ended June 30, 2025, compared to $3.41 million for the same period in 2024.
• Cash balance significantly decreased to $730,475 as of June 30, 2025, from $2.83 million at December 31, 2024.
• Cash used in operating activities increased to $2.43 million for the six months ended June 30, 2025, up from $1.91 million in the prior year period.
• Stockholders' equity declined to $569,859 as of June 30, 2025, from $2.20 million at December 31, 2024.
• The company received a Nasdaq notification for non-compliance with the minimum $2.5 million stockholders' equity requirement and was granted an extension until October 6, 2025, to regain compliance.
• MIRA is advancing its lead candidate, Ketamir-2, an oral ketamine analog for neuropathic pain, which is in an ongoing Phase 1 clinical trial with the second dosing cohort completed.
• The FDA cleared the Investigational New Drug (IND) application for Ketamir-2 on July 28, 2025, enabling U.S.-based clinical trials.
• Preclinical studies for MIRA-55, a non-psychoactive marijuana analog for anxiety and cognitive decline, demonstrated morphine-comparable pain relief without inflammation.
• MIRA entered a binding letter of intent on March 19, 2025, to acquire SKNY Pharmaceuticals, Inc., which is developing SKNY-1 for weight loss and smoking cessation.
• The SKNY acquisition is contingent on SKNY's valuation being equal to or greater than MIRA's, and SKNY is expected to provide a $5 million capital infusion upon completion.
• Post-period, in July 2025, MIRA raised approximately $2.2 million gross proceeds through its At-The-Market (ATM) equity offering facility and received $151,023 from option exercises.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including a 'going concern' warning and Nasdaq non-compliance due to critically low stockholders' equity and high cash burn. While there are positive clinical and preclinical developments for its drug candidates and a potential acquisition that could bring capital, the immediate financial risks are substantial and overshadow the operational progress for a seasoned investor.

Positives

• FDA cleared the Investigational New Drug (IND) application for Ketamir-2 on July 28, 2025, enabling U.S.-based clinical trials for neuropathic pain.
• Ketamir-2 is progressing in its Phase 1 clinical trial, with the second dosing cohort successfully completed and preparation for the third cohort underway.
• Preclinical results for topical Ketamir-2 demonstrated significant reduction in acute and inflammatory pain behaviors, with rapid onset and durable effect comparable to injected morphine.
• MIRA-55, a non-psychoactive marijuana analog, showed morphine-comparable pain relief in preclinical animal models without inducing local inflammation.
• The planned acquisition of SKNY Pharmaceuticals, Inc. is expected to expand the development pipeline with SKNY-1, targeting weight loss and smoking cessation.
• SKNY Pharmaceuticals is expected to provide a $5 million capital infusion upon merger completion, strengthening the balance sheet.
• Preclinical studies for SKNY-1 demonstrated weight loss, appetite suppression, reversal of nicotine-seeking behavior, and reversal of anxiety-related behavior.
• The U.S. DEA concluded that Ketamir-2 and MIRA-55 are not considered controlled substances under the Controlled Substances Act.
• Successfully raised approximately $2.2 million in gross proceeds through ATM sales in July 2025, post-period end, and an additional $151,023 from option exercises.

Negatives

• The company has sustained substantial losses and has insufficient cash and cash equivalents to support operations for at least the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Cash balance significantly decreased to $730,475 as of June 30, 2025, from $2.83 million at December 31, 2024.
• Stockholders' equity fell to $569,859 as of June 30, 2025, below Nasdaq's minimum requirement of $2.5 million.
• Cash used in operating activities increased to $2.43 million for the six months ended June 30, 2025, from $1.91 million in the prior year period, indicating increased cash burn.
• General and administrative expenses increased to $2.54 million for the six months ended June 30, 2025, from $2.12 million in the prior year period, primarily due to increased stock-based compensation.
• The company is highly dependent on obtaining significant additional external funding in the near term, with no assurance of success on commercially reasonable terms.
• The Nasdaq Capital Market listing is at risk if the company fails to regain compliance with the minimum stockholders' equity rule by October 6, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash and historical losses.
• Failure to obtain significant additional external funding in the near term could force the company to curtail operations.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement, risking delisting if compliance is not regained by October 6, 2025.
• The planned acquisition of SKNY Pharmaceuticals is contingent on an independent valuation concluding SKNY's value is at least equal to or greater than MIRA's.
• Reliance on related parties (MIRALOGX) for potential funding and the exclusive license for Ketamir-2.
• Uncertainty regarding the ability to obtain and maintain regulatory approval for product candidates.
• Challenges in successfully commercializing and marketing product candidates, if approved.
• Potential difficulties in contracting with and ensuring adequate performance from third-party suppliers, manufacturers, and service providers.
• Uncertainty regarding the potential market size, opportunity, and growth for product candidates.
• Risks associated with the initiation, timing, progress, and results of clinical studies and trials.
• The accuracy of estimates regarding expenses, capital requirements, and needs for additional financing.
• Ability to retain key professionals and recruit additional qualified personnel.
• The timing or likelihood of achieving various scientific, clinical, regulatory, and product development objectives.
• Uncertainty regarding the pricing and reimbursement of product candidates, if approved.
• The rate and degree of market acceptance of product candidates, if approved.
• Ability to establish and maintain intellectual property rights covering product candidates and technology.
• Developments relating to competitors and the broader industry could adversely affect the company.
• Major public health concerns could impact clinical trials, business operations, and funding requirements.

Future Outlook

The company anticipates beginning a Phase IIa clinical trial for Ketamir-2 in neuropathic pain by the end of 2025. It expects to continue generating losses in the foreseeable future and will require additional financing to fund operations, complete clinical development, and commercially launch product candidates. The company plans to secure additional capital through public equity offerings under its ATM Agreement and strategic transactions, including potential alliances and drug product collaborations. The planned acquisition of SKNY Pharmaceuticals, if completed, is expected to provide a $5 million capital infusion and expand the development pipeline.

Management Comments

• Management cannot provide assurance that the company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.
• If the company is unable to raise additional capital or secure additional lending in the near future, management expects that the company will need to curtail its operations.
• Management believes the planned strategic merger with SKNY Pharmaceuticals, Inc. in the third quarter of 2025, which is expected to add approximately $5 million in cash or other assets, will help cure the Nasdaq deficiency.
• Management also intends to utilize the approximately $6.6 million in available capital through the ATM offering facility to further strengthen the stockholders' equity position.

Industry Context

MIRA Pharmaceuticals operates in the highly competitive clinical-stage pharmaceutical development sector, focusing on neuroscience programs for neurologic and neuropsychiatric disorders. Its drug candidates, Ketamir-2 (a novel ketamine analog) and MIRA-55 (a pharmaceutical marijuana molecule), target significant unmet medical needs in pain, anxiety, and cognitive decline. The potential acquisition of SKNY Pharmaceuticals, with its focus on weight loss and smoking cessation, would diversify MIRA's pipeline into broader therapeutic areas, potentially leveraging the non-controlled substance status of its existing compounds. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles (e.g., FDA approval), making consistent external funding critical for survival and progress.

Comparison to Industry Standards

• The company's preclinical results for MIRA-55 demonstrating 'morphine-comparable pain relief' without inducing local inflammation suggest a potentially favorable efficacy and safety profile compared to standard opioid analgesics, which often carry significant side effects and addiction risks.
• SKNY-1's demonstrated 'reversal of anxiety-related behavior induced by a CB1 activator' distinguishes it from earlier CB1-targeting drugs that were discontinued due to unfavorable safety profiles, suggesting a potentially improved safety profile in this class.
• The FDA IND clearance for Ketamir-2 is a standard and critical milestone for pharmaceutical companies, allowing progression to U.S.-based human clinical trials, aligning with typical development pathways for novel drug candidates.
• The company's financial position, characterized by a 'going concern' warning and Nasdaq non-compliance due to low stockholders' equity, is significantly below industry standards for stable, publicly traded pharmaceutical companies and indicates a high level of financial risk compared to more established peers.

Corporate Governance

Legal Proceedings

• No material legal proceedings, government actions, administrative actions, investigations, or claims are currently pending against the company.
• The company anticipates expending significant financial and managerial resources in the future to defend its intellectual property rights and against claims of infringement by third parties.

Related Party Transactions

• The company has an exclusive license agreement with MIRALOGX, LLC (a related party with the same founder and largest shareholder) for Ketamir-2, involving an $0.1 million upfront payment and 8% quarterly royalty payments on net sales and other revenue.
• Issued a Common Stock Purchase Warrant to MIRALOGX for 700,000 shares at $2.00 per share, exercisable until November 15, 2028.
• Related party accounts receivable from MIRALOGX totaled $35,439 as of June 30, 2025, representing accounts payable paid on behalf of MIRALOGX, with no activity since December 31, 2024.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity offerings (ATM) to raise capital.
• Shareholders face substantial risk of delisting from Nasdaq due to non-compliance with minimum stockholders' equity requirements, which could adversely affect liquidity and share price.
• Shareholders face high investment risk due to the company's 'going concern' warning, indicating potential inability to fund operations without further capital.
• Employees and management may be impacted by potential curtailment of operations if sufficient funding is not secured.
• Customers (future patients) could benefit from the advancement of novel drug candidates for neuropathic pain, anxiety, and cognitive decline, if successfully developed and approved.
• Creditors face increased risk due to the company's precarious financial position and reliance on future capital raises.

Next Steps

• Initiate the third dosing cohort for the Phase 1 clinical trial of Ketamir-2.
• Begin a Phase IIa clinical trial for Ketamir-2 in neuropathic pain by the end of 2025.
• Proceed with the shareholder vote to approve the SKNY Pharmaceuticals merger at the Annual Meeting on September 11, 2025.
• Complete the financing transactions and evidence compliance with Nasdaq's minimum stockholders' equity rule on or before October 6, 2025.
• Continue to seek additional capital through public equity offerings (ATM) and strategic transactions to fund operations and future clinical trials.

Key Dates

Recommendation

Despite promising clinical and preclinical progress for its drug candidates and efforts to secure additional funding, MIRA Pharmaceuticals faces critical financial challenges. The explicit 'going concern' warning, coupled with a significant cash burn rate and non-compliance with Nasdaq's minimum stockholders' equity requirement, presents an immediate and severe risk to the company's viability and stock listing. While the potential SKNY acquisition and recent ATM raises offer some hope, they do not fully resolve the fundamental liquidity and solvency issues. A seasoned investor or institution would prioritize the high risk of delisting and potential operational curtailment over the long-term, speculative upside of the drug pipeline, making a 'sell' recommendation prudent to mitigate significant downside exposure.

Keywords

Pharmaceuticals, Neuroscience, Clinical-stage, Ketamir-2, MIRA-55, Neuropathic Pain, Inflammatory Pain, Neuropsychiatric Disorders, Neurocognitive Disorders, Weight Loss, Smoking Cessation, FDA IND Clearance, SEC Filing, 10-Q, Going Concern, Nasdaq Compliance, Biotech, Drug Development, Capital Raise, ATM Offering, SKNY Pharmaceuticals